[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA32771B1 - Mutants fgf21 et leurs utilisations - Google Patents

Mutants fgf21 et leurs utilisations

Info

Publication number
MA32771B1
MA32771B1 MA33815A MA33815A MA32771B1 MA 32771 B1 MA32771 B1 MA 32771B1 MA 33815 A MA33815 A MA 33815A MA 33815 A MA33815 A MA 33815A MA 32771 B1 MA32771 B1 MA 32771B1
Authority
MA
Morocco
Prior art keywords
polypeptides
fgf21 mutants
mutant fgf21
fgf21 polypeptides
treatment
Prior art date
Application number
MA33815A
Other languages
Arabic (ar)
English (en)
Inventor
Kenneth W Walker
Colin V Gegg Jr
Randy I Hecht
Edward J Belouski
Yue-Sheng Li
Mark L Michaels
Jing Xu
Murielle M Ellison
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32771B1 publication Critical patent/MA32771B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des molécules d'acides nucléiques codant pour des polypeptides FGF21 mutants, des polypeptides FGF21 mutants, des compositions pharmaceutiques comprenant des polypeptides FGF21 mutants et des procédés de traitement de troubles métaboliques au moyen desdits acides nucléiques, polypeptides ou compositions pharmaceutiques.
MA33815A 2008-10-10 2011-05-05 Mutants fgf21 et leurs utilisations MA32771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19576108P 2008-10-10 2008-10-10
PCT/US2009/060045 WO2010042747A2 (fr) 2008-10-10 2009-10-08 Mutants fgf21 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA32771B1 true MA32771B1 (fr) 2011-11-01

Family

ID=41571715

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33815A MA32771B1 (fr) 2008-10-10 2011-05-05 Mutants fgf21 et leurs utilisations

Country Status (21)

Country Link
US (2) US9279013B2 (fr)
EP (1) EP2358749B1 (fr)
JP (2) JP5878757B2 (fr)
KR (1) KR101651703B1 (fr)
CN (1) CN102625811B (fr)
AU (1) AU2009302318A1 (fr)
CA (1) CA2739615C (fr)
CL (1) CL2011000792A1 (fr)
CO (1) CO6362020A2 (fr)
CR (1) CR20110245A (fr)
EA (2) EA032727B1 (fr)
IL (1) IL212061A0 (fr)
MA (1) MA32771B1 (fr)
MX (1) MX341149B (fr)
NZ (1) NZ592009A (fr)
PE (1) PE20120021A1 (fr)
SG (1) SG195542A1 (fr)
TN (1) TN2011000161A1 (fr)
UA (1) UA105016C2 (fr)
WO (1) WO2010042747A2 (fr)
ZA (1) ZA201103356B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP2068909B1 (fr) 2007-03-30 2012-04-25 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CA2739615C (fr) * 2008-10-10 2017-12-05 Amgen Inc. Mutants fgf21 et leurs utilisations
RU2525393C2 (ru) 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
WO2011154349A2 (fr) * 2010-06-08 2011-12-15 Novo Nordisk A/S Analogues et dérivés du fgf21
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
MX2013002208A (es) 2010-08-23 2013-05-30 Amgen Inc Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN103717586A (zh) 2011-04-05 2014-04-09 安姆根有限公司 用于治疗糖尿病的与葡糖激酶调节蛋白相互作用的苯并二氧杂*和苯并二氧杂环己烯化合物
JP5836481B2 (ja) 2011-05-16 2015-12-24 ジェネンテック， インコーポレイテッド Ｆｇｆｒ１アゴニスト及び使用方法
RU2697762C2 (ru) 2011-07-01 2019-08-20 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции, применения и способы лечения нарушений и заболеваний обмена веществ
WO2013033452A2 (fr) 2011-08-31 2013-03-07 Amgen Inc. Procédé de traitement ou d'amélioration du diabète type i employant fgf21
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
CN108530535B (zh) 2012-02-15 2021-02-26 诺和诺德股份有限公司 结合肽聚糖识别蛋白1的抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
WO2013123444A1 (fr) 2012-02-17 2013-08-22 Amgen Inc. Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase
WO2013173382A1 (fr) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
NZ630469A (en) 2012-12-27 2017-02-24 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014149699A1 (fr) 2013-03-15 2014-09-25 Eli Lilly And Company Protéine bifonctionnelle
RU2707531C2 (ru) 2013-10-28 2019-11-27 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Модели рака и соответствующие способы
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
WO2015103782A1 (fr) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Mutant fgf21 et son conjugué
EP3097122B9 (fr) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
EP3125921B1 (fr) 2014-03-11 2020-07-08 Novartis AG Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
HUE065807T2 (hu) 2014-07-17 2024-06-28 Novo Nordisk As TREM-1 ellenanyagok helyspecifikus mutagenezise viszkozitás csökkentésére
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EA201791238A1 (ru) 2014-12-04 2018-02-28 Новартис Аг Способы и композиции, в которых используются варианты полипептидов klotho
MX2017007458A (es) 2014-12-23 2017-08-10 Novo Nordisk As Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2016179140A1 (fr) * 2015-05-05 2016-11-10 The Regents Of The University Of California Polymères à facteur de croissance des fibroblastes, procédés de fabrication associés et leurs applications
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CA3003616C (fr) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methodes de traitement de troubles associes aux acides biliaires
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (fr) 2016-06-22 2017-12-28 Novo Nordisk A/S Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (fr) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Peptide de liaison pour la construction d'une protéine de fusion
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19
CA3047862A1 (fr) 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
CN116098989A (zh) * 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
KR20200139219A (ko) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 항-trem-1 항체 및 이의 용도
JP7492463B2 (ja) 2018-07-03 2024-05-29 ブリストル－マイヤーズ スクイブ カンパニー Ｆｇｆ－２１製剤
KR20220125289A (ko) 2020-01-08 2022-09-14 브리스톨-마이어스 스큅 컴퍼니 Fgf-21 접합체 제제
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022032187A1 (fr) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose
WO2022115597A1 (fr) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Méthodes de traitement de maladies du foie

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
CA1310924C (fr) 1986-04-24 1992-12-01 Francis P. Mccormick Systeme d'administration d'un medicament a l'aide de particules infectieuses
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
EP0315456B1 (fr) 1987-11-05 1994-06-01 Hybritech Incorporated Immunoglobulines modifiées au moyen d'un polysaccharide présentant un potentiel immunogène réduit ou des cinétiques pharmacologiques améliorées
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
CA2063431C (fr) 1989-07-06 2002-10-29 Lewis T. Williams Recepteurs de facteurs de croisance fibroblastes
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
BR9007937A (pt) 1989-12-22 1992-11-17 Applied Research Systems Modificacao da expressao de gene endogeno com elemento regulador
WO1991010470A1 (fr) 1990-01-08 1991-07-25 Brown University Research Foundation Dispositifs et procedes d'apport ameliore de facteurs actifs
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
AU662107B2 (en) 1990-07-06 1995-08-24 Aventis Pharmaceuticals Inc. Fibroblast growth factor receptors
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DK0646182T3 (da) 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JPH11501201A (ja) 1993-05-07 1999-02-02 スターリング ウィンスロップ インコーポレイティド ラクトース加水分解牛乳及び味を改善し甘味を抑えた乳製品
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
WO1994029442A2 (fr) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Maitrise precise de l'expression des genes dans les cellules encaryotes au moyen de promoteurs reagissant a la tetracycline
WO1995005452A2 (fr) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
TR199701436T1 (xx) 1995-05-26 1998-03-21 Zeneca Limited Bir ekdison resept�r�n� i�eren bir gen anahtar�.
JPH11506722A (ja) 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
CA2244363C (fr) 1996-02-28 2006-11-14 Ariad Gene Therapeutics, Inc. Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
AU739057B2 (en) 1996-12-26 2001-10-04 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Novel polypeptide, novel DNA, and novel antibody
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP3653469B2 (ja) 1997-11-25 2005-05-25 ジェネンテック・インコーポレーテッド 線維芽細胞増殖因子−１９
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6369109B1 (en) 1998-10-28 2002-04-09 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor
WO2000027885A1 (fr) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EP1183051A2 (fr) 1999-03-15 2002-03-06 Chiron Corporation Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la pr vention des maladies de l'oeil
CA2311201A1 (fr) 1999-08-05 2001-02-05 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (fr) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE446365T1 (de) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic Menschliches fgf-21 gen und genexpressionsprodukte
WO2001038357A2 (fr) 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Nouveau membre de la famille des facteurs de croissance des fibroblastes, appele jaffa, et utilisations correspondantes
US7108984B2 (en) 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
WO2001049849A1 (fr) 2000-01-05 2001-07-12 Zymogenetics, Inc. Zfgf11 : nouvel homologue de fgf
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20040018499A1 (en) 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
WO2002102973A2 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation de proteine tyrosine kinase recepteur, procedes de criblage et utilisations
MXPA04000231A (es) 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
WO2003038054A2 (fr) 2001-10-31 2003-05-08 New York University Conception et synthese de type structurel d'inhibiteurs de facteur de croissance fibroblastique (fgf), et composes modulateurs de fgf
EP1469880A4 (fr) 2002-01-15 2006-04-26 Lilly Co Eli Methode de diminution de la morbidite et de la mortalite chez des patients gravement malades
EP1332761A1 (fr) 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistes des récepteurs du facteur de croissance des fibroblastes
CA2473810A1 (fr) 2002-01-31 2003-08-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agonistes du fgfr
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (ja) 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
CA2503390A1 (fr) 2002-11-01 2004-05-21 Genentech, Inc. Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2004056865A2 (fr) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Methode de modulation de l'interaction d'un recepteur et d'un ligand
WO2004083381A2 (fr) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
WO2005019258A2 (fr) 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP2060270A3 (fr) 2003-10-16 2009-12-09 Imclone LLC Inhibiteurs de récepteur 1 de facteur de croissance de fibroblaste et procédés de traitement associés
EA200601121A1 (ru) 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
EP1697420A2 (fr) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique
EP1727559A1 (fr) 2004-01-26 2006-12-06 Eli Lilly And Company Utilisation de fgf-21 et d'une thiazolidinedione pour traiter le diabete de type 2
EP1735340A2 (fr) 2004-03-17 2006-12-27 Eli Lilly And Company Composes fgf-21 lies au glycol
JP4505631B2 (ja) 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
EP2194064A1 (fr) 2004-05-13 2010-06-09 Eli Lilly & Company Protéines de fusion FGF-21
WO2006028595A2 (fr) 2004-09-02 2006-03-16 Eli Lilly And Company Muteines de facteur de croissance 21 de fibroblaste
EP1789443A1 (fr) 2004-09-02 2007-05-30 Eli Lilly And Company Muteines du facteur de croissance 21 du fibroblaste
JP5948627B2 (ja) * 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
WO2006065582A2 (fr) * 2004-12-14 2006-06-22 Eli Lilly And Company Muteines du facteur de croissance fibroblastique 21
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
JP2006246823A (ja) 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用
WO2006130527A2 (fr) 2005-05-31 2006-12-07 Novartis Ag Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
EP1995321A2 (fr) 2005-08-15 2008-11-26 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
WO2007055789A2 (fr) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression de proteines therapeutiques solubles
CA2644046A1 (fr) 2006-02-28 2007-09-07 Trustees Of Boston University Regulateurs metaboliques et leurs utilisations
CA2655504A1 (fr) 2006-06-15 2007-12-21 Fibron Ltd. Anticorps bloquant l'activation du recepteur du facteur de croissance des fibroblastes et leurs procedes d'utilisation
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
WO2008057683A2 (fr) 2006-10-03 2008-05-15 Novo Nordisk A/S Méthodes de purification de conjugués de polypeptides
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
EP2068909B1 (fr) * 2007-03-30 2012-04-25 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
WO2009009173A2 (fr) 2007-04-02 2009-01-15 Genentech, Inc. Klotho bêta
US8697369B2 (en) 2007-04-06 2014-04-15 National Institute Of Advanced Industrial Science And Technology Method for screening a test substance for activating a receptor associated with FGF 21 activity
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
US20100330062A1 (en) 2007-05-08 2010-12-30 Koeffler H Phillip Klotho protein and related compounds for the treatment and diagnosis of cancer
WO2008153705A2 (fr) 2007-05-22 2008-12-18 Novartis Ag Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2008149521A1 (fr) 2007-05-29 2008-12-11 Immuno-Biological Labolatories Co., Ltd Agent thérapeutique contre le cancer et procédé de traitement du cancer
CN101778937A (zh) 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
ES2646614T3 (es) 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010006214A1 (fr) 2008-07-09 2010-01-14 Ambrx, Inc. Anticorps de neutralisation de fgf-21 et leurs utilisations
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
CA2739615C (fr) * 2008-10-10 2017-12-05 Amgen Inc. Mutants fgf21 et leurs utilisations
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SI3248610T1 (sl) 2009-05-05 2024-03-29 Amgen Inc., Mutanti fgf21 in njihove uporabe

Also Published As

Publication number Publication date
CN102625811A (zh) 2012-08-01
US9279013B2 (en) 2016-03-08
AU2009302318A1 (en) 2010-04-15
UA105016C2 (uk) 2014-04-10
KR101651703B1 (ko) 2016-08-26
CO6362020A2 (es) 2012-01-20
JP2012504965A (ja) 2012-03-01
CA2739615A1 (fr) 2010-04-15
IL212061A0 (en) 2011-06-30
JP2015165801A (ja) 2015-09-24
CN102625811B (zh) 2016-09-21
ZA201103356B (en) 2012-02-29
JP5878757B2 (ja) 2016-03-08
PE20120021A1 (es) 2012-02-10
TN2011000161A1 (en) 2012-12-17
EA201100516A1 (ru) 2011-10-31
MX2011003788A (es) 2011-08-03
CR20110245A (es) 2011-08-29
SG195542A1 (en) 2013-12-30
EP2358749A2 (fr) 2011-08-24
CA2739615C (fr) 2017-12-05
EP2358749B1 (fr) 2018-07-18
WO2010042747A3 (fr) 2010-06-17
EA032727B1 (ru) 2019-07-31
MX341149B (es) 2016-08-09
US20160244497A1 (en) 2016-08-25
WO2010042747A2 (fr) 2010-04-15
NZ592009A (en) 2012-11-30
EA201990619A1 (ru) 2019-07-31
US20110195895A1 (en) 2011-08-11
KR20110093790A (ko) 2011-08-18
CL2011000792A1 (es) 2011-08-26

Similar Documents

Publication Publication Date Title
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
EA201001883A1 (ru) Мутанты fgf21 и их применение
EA201171220A1 (ru) Мутанты fgf21 и их применение
WO2010129600A3 (fr) Mutants de fgf21 et leurs utilisations
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009002816A (es) Proteinas de fusion de albumina.
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
TN2011000553A1 (en) Fgf21 mutants and uses thereof
UA102395C2 (en) Fgf21 mutants and use thereof
TN2010000563A1 (en) Fgf 21 mutants and uses thereof
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности